Zobrazeno 1 - 10
of 16
pro vyhledávání: '"A Morego-Soler"'
Autor:
V Cano Collado, A Trujillano Ruiz, V Llodra Ortola, MA Maestre Fullana, N Galan Ramos, MA Morego Soler
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance The integration of the hospital pharmacist into a multidisciplinary team is needed due to the increase in hospital admissions of complex chronic patients. Aim and objectives To describe discrepancies and potentially inapprop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42c3aea4db9d98ddd435aa27474ae1e0
https://doi.org/10.1136/ejhpharm-2021-eahpconf.197
https://doi.org/10.1136/ejhpharm-2021-eahpconf.197
Autor:
G Barrientos Ruiz, F Perello Rossello, F Amer Alomar, V. Llodrá Ortolá, M.A. Morey Riera, MM Crespi Magro, A Trujullano Ruiz, MA Maestre Fullana, V Cano Collado, N Galan Ramos, A. Morego Soler
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Calcitonin gene related peptide (CGRP) receptor inhibitors are a new group of drugs that have been included for migraine pharmacotherapy and migraine prevention. Erenumab and galcanezumab have notable individual variance and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::478662e19e43cece82bac13d2f72b79d
https://doi.org/10.1136/ejhpharm-2021-eahpconf.186
https://doi.org/10.1136/ejhpharm-2021-eahpconf.186
Autor:
B Arribas-Díaz, A Morego-Soler, N Manresa-Ramón, AM Rizo-Cerdá, A Bosó-Ribelles, V Bosó-Ribelles, MM Sanchez-Catalicio, Najera-Perez, I Sánchez-Martinez, P Selvi-Sabater
Publikováno v:
European Journal of Hospital Pharmacy. 21:A75.1-A75
Background Conversion from intravenous (IV) to oral treatment has many advantages, such as avoiding the adverse events attributed to IV treatment and using less costly drugs. It is also more comfortable, requires fewer human resources and it potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90727c54c64841d23ed7a660ffe69d42
https://doi.org/10.1136/ejhpharm-2013-000436.184
https://doi.org/10.1136/ejhpharm-2013-000436.184
Autor:
N Manresa Ramon, A. Boso Ribelles, T Alonso Dominguez, AM Rizo Cerdá, P Selvi Sabater, M Ventura López, B Arribas Díaz, I. Sánchez Martínez, A. Morego Soler, M.C. Sánchez Mulero
Publikováno v:
European Journal of Hospital Pharmacy. 21:A180.1-A180
Background Inappropriate prescribing is highly prevalent in older people and has become a global healthcare concern. Purpose To detect inappropriate prescriptions for patients hospitalised in the Internal Medicine Ward according to STOPP/START criter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dacd707e53cdc3e485ca2e7b9e846866
https://doi.org/10.1136/ejhpharm-2013-000436.441
https://doi.org/10.1136/ejhpharm-2013-000436.441
Autor:
N Manresa-Ramón, AM Rizo-Cerdá, I Sánchez-Martinez, MC Sanchez-Mulero, MM Sanchez-Catalicio, A Morego-Soler, B Arribas-Díaz, A Bosó-Ribelles, JC Titos-Arcos, P Selvi-Sabater
Publikováno v:
European Journal of Hospital Pharmacy. 21:A54.1-A54
Background Linezolid and vancomycin are the antibiotics most commonly used in the treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus . Purpose To study the mortality of inpatients diagnosed with pneumonia and treated with va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e0be5b0869d0119b236bac2bc78bb2f
https://doi.org/10.1136/ejhpharm-2013-000436.131
https://doi.org/10.1136/ejhpharm-2013-000436.131
Autor:
N Manresa-Ramón, AM Rizo-Cerdá, A Morego-Soler, I Sánchez-Martinez, MC Sanchez-Mulero, MM Sanchez-Catalicio, B Arribas-Díaz, JC Titos-Arcos, A Bosó-Ribelles, P Selvi-Sabater
Publikováno v:
European Journal of Hospital Pharmacy. 21:A54.3-A55
Background Pneumonia is one of the most common causes of mortality in geriatric patients. The appropriate antibiotic treatment of this pathology can decreases the mortality rate in the patient group. Purpose To study the features of the patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99879d3631f41874e4d2723b3e16cf56
https://doi.org/10.1136/ejhpharm-2013-000436.133
https://doi.org/10.1136/ejhpharm-2013-000436.133
Autor:
P Selvi Sabater, B Arribas Díaz, Nájera Pérez, I Sanchez Quiles, MA Morego Soler, I. Sánchez Martínez, AM Rizo Cerdá, N Manresa Ramon, I De Gorostiza Frias, M.M. Sanchez Catalicio
Publikováno v:
European Journal of Hospital Pharmacy. 21:A106.2-A106
Background Spanish laws include the special availability situation of drugs that can be used for ‘off label’ indications. Off-label use is regulated by the RD 1015/2009 from 19th June law. Purpose To study the drugs prescribed to be used for off-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d6c52d3933dd3bdffcacd9534699d65
https://doi.org/10.1136/ejhpharm-2013-000436.261
https://doi.org/10.1136/ejhpharm-2013-000436.261
Autor:
M.P. Molina-Guillen, I Sánchez-Martinez, JC Titos-Arcos, A. Morego Soler, N Manresa-Ramón, MM Sanchez-Catalicio, MC Sanchez-Mulero, B Gil-Rueda, B Arribas-Díaz, A Bosó-Ribelles
Publikováno v:
European Journal of Hospital Pharmacy. 20:A162.1-A162
Background Primary bacteraemia and bacteraemia caused by catheter infections entail a high pharmaceutical cost. The ‘Zero Bacteraemia Project’ (BZP) for central intravenous catheter (CVC) use in invasive therapies showed a decrease in the number
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::513392549bc48be4441d76c613531603
https://doi.org/10.1136/ejhpharm-2013-000276.449
https://doi.org/10.1136/ejhpharm-2013-000276.449
Autor:
Najera-Perez, I Sanchez-Quilez, A Morego-Soler, P Selvi-Sabater, N Manresa-Ramón, A Bosó-Ribelles, B Arribas-Díaz, I Sánchez-Martinez, AM Rizo Cerdá, MC Sanchez-Mulero
Publikováno v:
European Journal of Hospital Pharmacy. 20:A128.2-A128
Background In renal failure, alteration in the pharmacokinetics increases the frequency of overdoses. Purpose To evaluate pharmaceutical care using a computer programme for drug dose adjustment in renal failure. Materials and Methods The study period
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::709cc32a8a772fecc0ad6e3dee05cd72
https://doi.org/10.1136/ejhpharm-2013-000276.354
https://doi.org/10.1136/ejhpharm-2013-000276.354
Autor:
B Arribas-Díaz, I Sánchez-Martinez, P Selvi-Sabater, MC Sanchez-Mulero, C Castilla-Llorente, A Bosó-Ribelles, A Morego-Soler, N Manresa-Ramón, AM Rizo-Cerdá, A. Espuny Miró
Publikováno v:
European Journal of Hospital Pharmacy. 20:A134.2-A134
Background Tacrolimus is a drug metabolised by CYP3A4. Since imatinib increases the plasma concentrations of simvastatin, a CYP3A4 substrate, this indicates that it is an inhibitor of this enzyme and may affect other drugs. Purpose To describe the po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad428fb48d6232204afd506b16b5c797
https://doi.org/10.1136/ejhpharm-2013-000276.371
https://doi.org/10.1136/ejhpharm-2013-000276.371